Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Maged K Elsayad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Nasr City 11751, Cairo, Egypt. Hauptthemen laut MEDLINE: Dabigatran, Polymethacrylic Acids, Antithrombins. Die Arbeit nennt 68 Literaturangaben.
Abstract (Originalsprache)
Objectives
Dabigatran etexilate (DAB), a direct thrombin inhibitor, exhibits limited oral bioavailability (6%–7%), mostly attributable to pH-dependent solubility. To address this issue, Eudragit S100 (EU)-coated liposomes were engineered to safeguard DAB-loaded nanocarriers in the stomach and provide targeted release in the intestine, where absorption occurs through several mechanisms.
Methods
Liposomal vesicles were prepared using the conventional thin film hydration method. The developed formulations were subjected to physicochemical characterization, which included Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), zeta potential analysis, particle size measurement, polydispersity index (PDI) assessment, entrapment efficiency (EE%), and transmission electron microscopy (TEM). Key findings The selected formulation, EU@DAB-Lip4, exhibited advantageous properties: minimal particle size (136.9 nm), high EE (92.67%), and colloidal stability (zeta potential −17.3 mV). In vitro release demonstrated pH-responsive behaviour, with low gastric release (12.8% at 2 hr) and enhanced intestinal release (75.5% at pH 7.4). Pharmacokinetic studies in rats demonstrated a 5.6-fold and 2.7-fold enhancement in bioavailability for EU@DAB-Lip4 relative to DAB-Lip and DAB suspension, respectively, as indicated by elevated Cmax (2664 vs. 891 and 554 ng/ml) and AUC₀−∞ (21 020 vs. 7236 and 3749 ng.hr/ml).
Conclusions
EU-coated liposomes constitute a viable platform for enhancing DAB bioavailability and therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Nasr City 11751, Cairo, Egypt.
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Menoufia National University, 70 km Cairo-Alexandria Agricultural Road, Menofia, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk, 71491, Saudi Arabia.
- Department of Pharmaceutics & Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Sixth of October City 12585, Central Axis- Part 1/1- Behind Sixth of October City Authority, Giza, Egypt.
ORCID-Profile: Maged K Elsayad, Abdulsalam M Kassem, Elsaied H Barakat, Walid Anwar, Ayman Salama, Eman A Bseiso
Zitieren
APA
Elsayad, M. K., Kassem, A. M., Barakat, E. H., Anwar, W., Salama, A., & Bseiso, E. A. (2026). Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf103
Vancouver
Elsayad MK, Kassem AM, Barakat EH, Anwar W, Salama A, Bseiso EA. Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf103
BibTeX
@article{Elsayad2026,
author = {Elsayad, Maged K and Kassem, Abdulsalam M and Barakat, Elsaied H and Anwar, Walid and Salama, Ayman and Bseiso, Eman A},
title = {Eudragit S100–coated liposomes: a pH-responsive strategy to overcome dabigatran etexilate’s oral bioavailability challenge},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf103}
}
EUVIMED